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The epidemic of obesity imposes unprecedented challenges on
human adipose tissue (WAT) storage capacity that may benefit
from adaptive mechanisms to maintain adipocyte functionality.
Here, we demonstrate that changes in the regulatory feedback set
point control of Insig1/SREBP1 represent an adaptive response
that preserves WAT lipid homeostasis in obese and insulin-
resistant states. In our experiments, we show that Insig1 mRNA
expression decreases in WAT from mice with obesity-associated
insulin resistance and from morbidly obese humans and in in
vitro models of adipocyte insulin resistance. Insig1 downregula-
tion is part of an adaptive response that promotes the mainte-
nance of SREBP1 maturation and facilitates lipogenesis and
availability of appropriate levels of fatty acid unsaturation, par-
tially compensating the antilipogenic effect associated with insu-
lin resistance. We describe for the first time the existence of this
adaptive mechanism in WAT, which involves Insig1/SREBP1 and
preserves the degree of lipid unsaturation under conditions of
obesity-induced insulin resistance. These adaptive mechanisms
contribute to maintain lipid desaturation through preferential
SCD1 regulation and facilitate fat storage in WAT, despite on-
going metabolic stress. Diabetes 62:3697–3708, 2013
T
he epidemic of obesity is testing the capacity of
white adipose tissue (WAT) to cope with an un-
precedented nutritional pressure and demand to
expand. We and others have proposed that the
expansion and dysfunction of WAT may be an important
pathogenic contributor to obesity-associated metabolic
complications (1). However, a recurrent observation from
clinical studies is that obese patients maintain a remark-
able capacity to store fat before adverse metabolic effects
occur. Moreover, we have recently demonstrated, using a
monozygotic twin cohort discordant for obesity, that while
expanding, the WAT adapts its biochemical features to
maintain its biophysical characteristics and preserves its
functionality by increasing the degree of fatty acid (FA)
unsaturation and chain length in adipocyte membrane
phospholipids (PLs). This implies the existence of adap-
tive homeostatic mechanisms that preserve WAT func-
tionality (2).
Intrigued by these and other observations showing that
improving WAT expandability and storage capacity ame-
liorates insulin sensitivity (3), we hypothesized the exis-
tence of adaptive responses that optimize fat storage and
preserve WAT homeostasis. These adaptations may help
WAT to cope with the added storage demands imposed by
a positive energy balance through changes in transcrip-
tional and biochemical cycles. The interest in identifying
these adaptive mechanisms is fueled by their potential as
biomarkers of metabolic stress (4), with diagnostic, prog-
nostic, and therapeutic value in human obesity.
SREBPs are transcription factors that control genes in-
volved in FA and triglyceride (TG) synthesis via SREBP1 or
cholesterol biosynthesis through SREBP2. Owing to alter-
native splicing, two isoforms of SREBP1 exist. The highly
active Srebp1a isoform is predominantly expressed in vitro,
whereas Srebp1c, a less active form, is predominantly ex-
pressed in vivo. Demonstrated SREBP1 targets include
genes involved in rate-limiting de novo lipogenesis steps
(e.g., acetyl-CoA carboxylase [Acc] and FA synthase [Fas])
(5–7), FA desaturation (e.g., stearoyl-CoA desaturase 1
[Scd1]) (6,8) and elongation (e.g., elongase 6 [Elovl 6])
(9,10), FA re-esterification (e.g., mitochondrial glycerol-
3-phosphate acyltransferase [Gpat1]) (11), and PL synthesis
(e.g., CTP: phosphocholine cytidylyltransferase a [Ccta])
(12,13). Given these pleiotropic effects of SREBP1 on lipid
metabolism, we hypothesized that SREBP1 may play a
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leading role in adaptive responses in WAT. Moreover, be-
cause a key event in this response is the post-translational
maturation and activation of SREBP1 and this process is
highly dependent on the activity of insulin-induced genes 1
and 2 (Insig1 and Insig2), we hypothesized that the set
point linking SREBP1 and Insig1 may be important for the
process of WAT adaptation to excess lipid storage.
It is well established that under conditions character-
ized by high sterol levels or elevated polyunsaturated/
unsaturated FAs, SREBP1 is physiologically inactivated.
Under these conditions, SREBP1 remains anchored in the
endoplasmic reticulum (ER) as part of a tripartite complex
with SREBP cleavage-activating protein (SCAP) and Insig1
or Insig2 (14,15), which exert a permissive retaining effect
on SREBP1, preventing its maturation and activation. This
regulatory system is highly sensitive and rapidly activated
in response to conditions requiring SREBP1 activation (e.g.,
decreased polyunsaturated FA, anabolic effects of insulin, or
excess saturated FA). In these situations, the ER–anchoring
activity of Insigs is diminished, allowing SCAP to escort
SREBP1 from the ER to the Golgi to be cleaved, producing
a soluble and transcriptionally active SREBP1 mature protein.
The importance and dependence on Insig1 for the reg-
ulation of SREBP1 activity and lipogenic capacity has been
demonstrated in vitro and in vivo. Overexpressing Insig1
in 3T3-L1 adipocytes inhibits both adipogenesis and lipid
accumulation (16). Similarly, peroxisome proliferator–
activated receptor-g agonists can induce Insig1 expression
in vitro and in vivo in WAT (17,18) while promoting adi-
pocyte differentiation, suggesting that Insig1 acts as a
control set point to limit the amount of fat that can be
stored under anabolic conditions. Coordinating this regu-
lation, insulin itself can activate SREBP1 and promote
lipogenesis, while, simultaneously, Insig1 expression is
induced and restricts further SREBP1 activation. This
has been demonstrated in vitro (17,19,20) and in vivo (21).
These findings indicate a physiological negative feedback
regulatory loop consisting in the regulation of Insig1 ex-
pression by SREBP1 in order to finely control its own
cleavage. Akin to that, this type of autoregulatory feedback
loop has already been suggested for the physiological control
of cholesterol synthesis in liver via Insig1/SREBP (21,22).
However, pathophysiological dysregulation of this loop in
WAT in the context of obesity has never been considered.
In addition to genes involved in de novo synthesis of FAs
and TG storage, SREBP1-target genes are also involved
in the supply of specialized FAs used for critical cellular
roles, including maintenance of membrane lipid homeo-
stasis, lipid modification of proteins, and effectors of in-
tracellular signaling (23). On the basis of previous knowledge,
we hypothesized that in an insulin-resistance (IR) state,
the downregulation of Insig1 will lead to a resetting of the
physiological negative Insig1/SREBP1 regulatory feedback
loop to optimize active SREBP1 levels in an attempt to
maintain adipose lipid homeostasis and preserve the syn-
thesis of specific lipid species essential for cell function-
ality. A similar concept has been described in a recent
report that showed that in Caenorhabditis elegans and
mammalian cells, genetic limitation in the biosynthesis of
phosphatidylcholine (PC) PLs led to changes in membrane
composition and functionality, promoted increased levels
of nuclear mature SREBP1, and elevated lipogenesis. This
study proposes a conserved feedback loop responding to
PC levels and ensuring adequate levels of PC production
(24). In a different experimental model, perturbation of
phosphatidylethanolamine (PE) synthesis in the Drosophila
heart leads to alteration in PE distribution in cardiac sar-
colemmal membranes. Attempts to compensate this specific
lipid perturbation involved adaptive elevation in SREBP1
mature protein levels and inappropriately increased lipo-
genesis (25) and associated pathology.
Here, we investigate whether coordinated regulation
of Insig1/SREBP1 could work as an adaptive mechanism
facilitating lipid biosynthesis to maintain WAT lipid
homeostasis, defying the recognized antilipogenic effect
determined by IR. In agreement with this model, our
results indicate that decreased Insig1 expression in WAT
is a common feature of murine models of diet- and genetic-
induced obesity exposed to excessive nutrient pressure
and is operative in human obesity and IR. In support of this
concept, we have in vitro and in vivo evidence that de-
creased Insig1, as observed in obese individuals, facili-
tates adipocyte differentiation and fat deposition. Finally,
we discuss whether this adaptive response may contribute
to preserve lipid generation and storage under adverse
metabolic conditions.
RESEARCH DESIGN AND METHODS
Human samples. All subjects from the five cohorts studied gave their consent
after being informed of the nature, purpose, and possible risks of the different
studies. All ethical committees gave their approval.
Animal care. Animals were housed in a temperature-controlled room with
a 12-h light/dark cycle. Food and water were available ad libitum.Mice were fed
a standard chow diet or a 45% high-fat diet (HFD; Research diet D12451)
according to the experiment. All animal protocols were approved by the U.K.
Home Office and the University of Cambridge, and mice were cared for
according to the Guiding Principles for Research Involving Animals and Hu-
man Beings. The ob/ob and lean control mice (mix 129Sv-C57BL6) were gen-
erated as described in Medina-Gomez et al. (26).
Insig1 knockout mouse. This mouse was generated by AstraZeneca Trans-
genics and Comparative Genomics (ATCG), AstraZeneca R&D MoIndal (Sweden)
(Supplementary Fig. 11). For this study, tissue samples were collected from 11- to
12-week-old male mice. Dual-energy X-ray absorptiometry (Lunar Corpora-
tion) was used to measure body composition.
Cell culture and in vitro insulin resistance studies. 3T3-L1 preadipocytes
were cultured as previously reported (27). IR was induced at day 9 of differ-
entiation by incubating the cells in Dulbecco’s modified Eagle’s medium
(25 mmol/L glucose) containing 100 nmol/L insulin for 16 h.
Stable Insig1 knockdown 3T3-L1 cell line. Insig1 stable knockdown and
control cell line were generated as previously described (28). Cells were
cultured, differentiated into adipocytes, and stained for Oil-Red-O, as described
previously (29). TG content was determined as previously reported (30).
RNA preparation and qRT-PCR. RNA extraction quantitative (q)RT-PCR
were performed as previously reported (26,28). The input value of the gene of
interest was standardized to 18S.
Western blot analysis. Protein isolation from cells and murine and human
adipose tissue was carried out as reported (28,31). Proteins were electro-
transfered on polyvinylidene fluoride membranes (Millipore) and probed with
phosphorylated (p)AKT (Thr308), total AKT, a-tubulin (Cell Signaling),
SREBP1 (Santa Cruz Biotechnology), INSIG1, and b-actin (Abcam) antibodies.
Total FA profiling-gas chromatography–mass spectrometry experiments.
Lipid profiling of adipose tissue (human and murine) was assessed by gas
chromatography–mass spectrometry as described (32). Subfractionation of
adipose tissue was performed as reported (33). Shotgun lipidomics were
performed as described previously (26,34).
De novo FA synthesis assay. Insig1 KD and control cells were differentiated
in 24-well plates. After overnight serum starvation, both cell lines were treated
with or without 200 nmol/L C75 (a Fas inhibitor) and with or without insulin
for 30 min before adding 13C-labeled sodium acetate into the medium. In-
corporation of 13C-sodium acetate into lipids was assessed during 60 min.
Cells were then lysed with 1 volume of 1N KOH, and the supernatant was
transferred to a screwtop vial. Subsequently, 1 volume of 5 mol/L KOH in 15%
methanol was added and the lysate heated for 45 min at 65°C to saponify. Then
1 volume of cold 5 mol/L HCL was added to acidify the reaction in a fume
cupboard, followed by the addition of 1 volume of cold absolute ethanol.
Saponified lipids were extracted twice by adding 7.5 volume of n-hexane.
Hexane containing the radioactive lipid mixture was mixed with the com-
patible organic solvent scintillate, and radioactivity was measured using liquid
scintillation counter.
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Statistical analysis. The data presented here were analyzed using SPSS 19
software (IBM) using ANOVA, a general-linear model for ANCOVA, and the
Student t test (unpaired). The significance level was set at P , 0.05. Principle
component analysis was carried out using Simca 12 software (Umetrics).
RESULTS
Downregulation of Insig1 and Srebp1 mRNA and
maintenance of SREBP1 mature protein in WAT of
murine models of diet- and genetic-induced obesity.
We examined whether Srebp1 and Insig1 mRNA levels
were altered in hypertrophic white adipocytes from mice
undergoing nutritional excess, obesity, and IR. Our data
show that 6 months on the HFD caused obesity and IR, as
indicated by decreased levels of p-AKT in WAT (Supple-
mentary Fig. 1A). At the transcriptional level, Srebp1c and
Insig1 mRNA expression was decreased (Fig. 1A). These
changes were not observed after 15 days on the HFD
(Fig. 1B), when carbohydrate metabolism was still unaf-
fected and the animals were healthy and actively ex-
panding their WAT (Supplementary Fig. 1B). Interestingly,
despite a reduction in Srebp1c mRNA expression, 6 months
on the HFD was associated with increased levels of tran-
scriptionally active mature SREBP1 protein in WAT com-
pared with chow-fed animals (Fig. 1C and Supplementary
Fig. 1C). Maintenance of SREBP1 maturation may result
from reduced Insig1 mRNA expression. Of note, the level
of SREBP1 protein was similar in WAT from 15 days’ HFD
and chow-fed animals (Fig. 1D and Supplementary Fig. 1D).
We also examined Srebp1c and Insig1 in WAT from
genetically obese and IR ob/ob mice. At 4 months of age,
when ob/ob mice are severely obese, hyperglycemic, and
IR (26), expression of both Srebp1c and Insig1 mRNA in
WAT is decreased compared with lean, insulin-sensitive
control mice (Fig. 1E). Of note, this is not a leptin
deficiency–dependent effect because levels of Srebp1c and
Insig1 mRNA are increased in young 1-month-old ob/ob
mice (Fig. 1F), when they are still insulin-sensitive and
glucose-tolerant, as indicated by increased markers of
insulin sensitivity (e.g., Glut4 [Fig. 1F] and Adiponectin
(26)). At 1 month of age, ob/ob mice show active expan-
sion of their WAT, and as observed previously in the diet-
induced obesity (DIO) model, the WAT of ob/ob mice at 1
and 4 months of age showed similar levels of SREBP1
active protein with respect to wild-type (WT) littermates
(Fig. 1G and H and Supplementary Fig. 1E and F) irre-
spectively of their gene expression pattern. Further sup-
port for discordant regulation of SREBP1 in lean and
obese mice came from analyses of adipocyte sizes in
10-week-old ob/ob mice. In line with the concept that
larger adipocytes are associated with IR, we found a nega-
tive correlation between adipocyte size and SREBP1 mature
protein levels (Supplementary Fig. 10E) in both the ob/ob
and WT mice. However, the levels of SREBP1 for a given
size of adipocyte were five times higher in the ob/ob mice.
Insig1 and Srebp1mRNA are specifically downregulated
in adipocytes of morbidly obese humans. We next de-
termined whether the same Insig1/SREBP1 adaptive changes
were observed in human WAT. We analyzed Srebp1 and
Insig1 in WAT from lean (BMI 22.26 0.8 kg/m2), obese (BMI
30.2 6 1.1 kg/m2), and morbidly obese (MO) (BMI 48.96 1.8
kg/m2) human subjects (Supplementary Table 1, cohort 1).
Expression of Insig1 mRNA was severely decreased in
omental (Om) and subcutaneous (SC) isolated adipocytes
from obese and MO compared with lean individuals (Fig.
2A). In the same isolated adipocyte samples, Srebp1c and
Srebp1a mRNAs were also specifically reduced in MO
compared with lean and obese individuals (Fig. 2B). In an
independent set of human samples (Supplementary Table 1,
cohort 2), we confirmed that INSIG1 protein levels were
reduced in SC WAT from MO (BMI 50.5 6 5.0 kg/m2)
compared with lean subjects (BMI 25.1 6 0.9 kg/m2)
(Fig. 2C).
IR leads to Insig1 downregulation in SC adipose
tissue, resulting in maintenance of mature SREBP1
protein. We then compared SC WAT from MO subjects
showing different degrees of IR (MO non-IR, BMI 39.0 6
4.27 kg/m2, homeostasis model assessment [HOMA] 2.31 6
0.44; and MO IR, BMI 41.96 1.84 kg/m2, HOMA 4.406 0.51,
respectively) versus slightly overweight control subjects
(BMI 26.1 6 1.19 kg/m2, HOMA 1.57 6 0.19) (Supplemen-
tary Table 1, cohort 3) to assess whether different degrees
in obesity (BMI) and IR status affected Insig1/SREBP1.
Srebp1 mRNA level was preserved in adipocytes from MO
non-IR versus control subjects, yet was significantly de-
creased in MO adipocytes from IR subjects (Fig. 2D). In
addition, Insig1 expression was significantly decreased in
MO non-IR and further decreased in MO IR (Fig. 2D) ver-
sus overweight individuals, and this was associated with
maintenance of similar levels of mature SREBP1 protein
among the three experimental groups (Fig. 2E). Assess-
ment of INSIG1 and SREBP1 protein expression in SC
WAT of an independent cohort (Supplementary Table 1,
cohort 4) of MO subjects with more extreme BMI and
a different degree of IR, MO non-IR (BMI 56.726 1.71 kg/m2,
HOMA 3.60 6 0.32), and IR (BMI 56.30 6 1.65 kg/m2,
HOMA 12.76 6 1.25) showed significantly lower INSIG1
protein levels in the more IR patients (Supplementary
Fig. 2A), whereas the mature form of SREBP1 was present
in similar amount between the two groups (Supplementary
Fig. 2B). A similar analysis performed in Om adipose tissue
of the same cohort (Supplementary Fig. 3A and B) re-
vealed a comparable level of expression of mature SREBP1
and INSIG1 proteins among lean, MO non-IR, and MO IR.
Globally considered, these results indicate that the changes
in Insig1 may be predominantly driven by IR and that
changes in Insig1 protein levels are preferentially affected in
the human SC adipose tissue, suggesting that the SC depot
may be more affected by metabolic stress than the OmWAT
depot (35,36).
Using an in vitro model of induced IR in 3T3-L1 adipo-
cytes that showed decreased levels of p-AKT (Supplementary
Fig. 4A), Glut4, and Adiponectin mRNA (Supplementary
Fig. 4B), we recapitulated the changes in Srebp1 and
Insig1 observed in vivo (Supplementary Fig. 4C and D),
further supporting a primary mechanistic role for IR in
Insig1 and SREBP1 changes.
Maintained mature SREBP1 levels in MO-derived
adipocytes maintain expression of genes regulating
unsaturation and TG re-esterification. Expression
analysis of SREBP1-target genes in isolated Om- and SC-
derived human adipocytes from lean, obese, and MO
individuals (Fig. 3A and B, respectively, and Supplemen-
tary Table 1, cohort 1) showed that the de novo FA syn-
thesis genes—Acc1 and Fas—were significantly reduced in
Om and SC adipocytes from MO subjects (BMI 48.9 6 1.8
kg/m2) compared with lean (BMI 22.2 6 0.8 kg/m2) or
obese (BMI 30.2 6 1.1 kg/m2) adipocytes. Of relevance,
the expression of Scd1 was relatively conserved in
obese adipocytes, only showing a moderate decrease
when lean and MO SC adipocytes were compared.
Similarly, Ccta expression was conserved in obese adi-
pocytes and only significantly reduced in the MO-derived
S. CAROBBIO AND ASSOCIATES
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FIG. 1. Analysis of Insigs and Srebp1 mRNA expression and of SREBP1 mature protein levels in murine models of diet- and genetic-induced
obesity. RT-PCR analysis was performed on RNA obtained from gonadal WAT of male WT C57BL6 mice fed an HFD for 6 months (n = 7 HFD; n = 9
chow) (A) or 15 days (n = 8 each group) (B) vs. their respective controls fed a standard chow diet and from gonadal WAT of males ob/ob and WT
littermates when mice were 4 months old (n = 9 WT n = 8 ob/ob) (E) or 1 month old (n = 8 WT, n = 6 ob/ob) (F). Western blot analysis of SREBP1
mature protein levels was performed on gonadal WAT of the same groups of mice: WT C57BL6 mice fed an HFD for 6 months (n = 7 HFD; n = 7
chow) (C) or 15 days (n = 7 each group) (D) vs. their respective controls fed a standard chow diet and on gonadal WAT of male ob/ob and WT
littermates when mice were 4 months old (n = 4 for both WT and ob/ob) (G) or 1 month old (n = 4 for both WT and ob/ob) (H). SREBP1 mature
protein was normalized to a-tubulin as the loading control. Blots were analyzed by densitometry. WT C57BL6 fed 6 months on the HFD vs. chow
diet: *P < 0.05, **P < 0.01, ***P < 0.001. WT vs. ob/ob: *P < 0.05, **P < 0.01, ***P < 0.001. Data are presented as mean 6 SEM.
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Om adipocytes compared with lean. Expression of
genes involved in FA re-esterification (e.g., Gpat1 and
Dgat1 [diacylglycerol O-acyltransferase 1]) was main-
tained in the obese population in both adipose depots
independently of their IR status. As previously shown
(37,38), Glut4 mRNA was markedly decreased in adi-
pocytes from IR obese and MO subjects when compared
with lean.
The same pattern of SREBP1 target genes expression
was observed in our IR 3T3-L1 in vitro model (Supple-
mentary Fig. 4E) and our DIO and ob/ob murine models
(Supplementary Fig. 5A and C) when they developed IR.
When still insulin-sensitive, WAT from mice fed the HFD
for 15 days and 1-month-old ob/ob mice exhibited a similar
lipogenic gene expression pattern compared with their
control littermates (Supplementary Fig. 5B and D).
Altogether, these data suggest that the combination of
reduced Insig1 expression and optimized maturation of
SREBP1 in WAT of the MO population was associated with
maintained FA desaturation and re-esterification SREBP1-
dependent pathways.
Decreased expression of Insig1 facilitates TG
accumulation and accelerates differentiation of 3T3-
L1 cells. It has previously been shown that Insig1 mRNA
levels increase during differentiation of 3T3-L1 and that
its overexpression decreases lipid accumulation during
FIG. 2. Insig1 and Srebp1 mRNA and protein levels in white adipocytes of non-IR and IR MO subjects. RT-PCR analysis was performed on RNA
obtained from mature adipocytes isolated from SC or Om depots from lean (BMI 22.2 6 0.8 kg/m2), obese (BMI 30.2 6 1.1 22.2 6 0.8 kg/m2), and
MO (BMI 48.9 6 1.8 22.2 6 0.8 kg/m2) human subjects (Supplementary Table 1, cohort 1), examining Insig1/2 (A) and Srebp1c/a (B) mRNA levels,
standardized to 18S mRNA within each group (n = 10 lean, n = 10 obese, n = 12 morbid obese). MO vs. lean: *P < 0.05, **P < 0.01, ***P < 0.005,
****P < 0.0005. MO vs. obese: &P < 0.05. ANOVA: $P < 0.05, $$P < 0.005. C: Western blot analysis of INSIG1 protein in SC white adipocytes from
lean (BMI 25.1 6 0.9 kg/m2) and MO (BMI 50.5 6 5.0 kg/m2) (Supplementary Table 1, cohort 2). The blots from SC samples were analyzed by
densitometry, and INSIG1 protein levels were normalized to b-actin as a loading control (n = 6 lean, n = 6 MO). MO vs. lean: *P < 0.05 **P < 0.01.
D: RT-PCR analysis was performed on RNA obtained from SC WAT from overweight (BMI 26.1 6 1.19 kg/m2, HOMA 1.57 6 1.19), MO non-IR (BMI
39.0 6 4.27 kg/m2, HOMA 2.31 6 0.44), and MO IR (BMI 41.9 6 1.84 kg/m2, HOMA 4.40 6 0.51) human subjects (Supplementary Table 1, cohort 1)
examining Srebp1/Insig1 mRNA expression (n = 6 overweight, n = 4 MO non-IR, n = 4 MO IR). MO non-IR and IR vs. overweight: *P < 0.05, **P <
0.005. MO non-IR vs. IR: &P < 0.05. ANOVA: $P < 0.005. E: Mature SREBP1 protein levels were determined in these groups by Western blot
analysis and normalized to b-actin. Blots were analyzed by densitometry (n = 4 overweight, n = 3 MO non-IR, n = 3 MO-IR). Data are presented as
mean 6 SEM.
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adipogenesis (16). We examined whether decreasing
Insig1, as observed in SC WAT of obese IR individuals,
facilitated lipid accumulation in adipocytes. To address
this question, stable Insig1 KD and control cell lines were
generated. Gene expression analysis performed in these
cells cultured at low glucose (5 mmol/L) and high glucose
(25 mmol/L) concentrations showed a reduction of Insig1
mRNA of 60–80% (Fig. 4A and Supplementary Fig. 6A).
Notably, Insig2mRNA levels were unchanged (Fig. 4A and
Supplementary Fig. 6A). In the absence of Insig1, Srebp1c
was upregulated, regardless of glucose concentration (Fig.
4A and Supplementary Fig. 6A), whereas Srepb1a mRNA
levels were significantly increased only at 5 mmol/L glu-
cose (Fig. 4A). Srebp1 upregulation was associated with
a significant increase in mature SREBP1 in I1KD cells
versus controls (Fig. 4B and Supplementary Fig. 6B).
I1KD cells showed increased lipid accumulation com-
pared with controls, regardless of glucose concentration,
as shown by Oil-Red-O staining (Fig. 4C and Supplemen-
tary Fig. 6C) and measurement of TG content (Fig. 4D and
Supplementary Fig. 6D). Increased TG levels in I1KD cells
corresponded with increased expression of lipogenic
genes (Fig. 4E and Supplementary Fig. 6E), particularly
Scd1, at both low and high glucose concentrations. The
primary effects of decreased Insig1 on fat deposition and
Scd1 expression were confirmed by de novo lipogenesis
assay and lipidomic analysis performed on I1KD cells ver-
sus controls. The functional relevance of Insig1 knockdown
was confirmed because the de novo lipogenesis func-
tional assay showed that I1KD cells incorporated more
13C-sodium acetate than control cells after 1 h incubation,
an effect that was further enhanced by insulin (Fig. 4F).
In support of a preferential effect on desaturation, global
free FA profile performed on Insig1 KD cells showed that
Insig1 depletion led to a significant increase in the desat-
uration indexes (C18:1n9/18:0, C16:1n7/16:0, and C14:1n5/
14:0) associated with SCD1 activity (Fig. 4G).
Insig1 knockout WAT and adipocyte primary culture
show increased Srebp1, SREBP1 lipogenic target
gene expression, and augmented lipid accumulation.
The results of the Insig1 KD in vitro model were validated
in vivo using an Insig1 knockout (KO) mouse (generation
strategy described in Supplementary Fig. 11). Although
this murine model has a complex phenotype characterized
by being lighter (Supplementary Fig. 7A–C) and shorter
(Supplementary Fig. 7B), it is useful to study the effects of
Insig1 genetic ablation without the confounding effect of
IR on lipogenesis. In support of a facilitated fat deposition
phenotype, Insig1 KO mice exhibit an increased percent-
age of fat mass (Fig. 5A) and increased gonadal and
FIG. 3. SREBP1 target genes expression in omental and subcutaneous white adipocytes of lean, obese, and MO. RT-PCR analysis was performed on
RNA obtained from mature adipocytes isolated from lean (BMI 22.2 6 0.8 kg/m2), obese (BMI 30.2 6 1.1 kg/m2), and MO (BMI 48.9 6 1.8 kg/m2)
(Supplementary Table 1, cohort 1). Adipocytes derived from Om (A) and SC depots (B) were examined and standardized to the average 18S mRNA
value within each group (n = 10 lean, n = 10 obese, n = 12 MO). Obese and MO vs. lean: *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001. MO vs.
obese: #P < 0.05, ##P < 0.01, ###P < 0.005. ANOVA: $P < 0.05, $$P < 0.005, $$$P < 0.001. Data are presented as mean 6 SEM.
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FIG. 4. Insig1 knockdown results in increased TG accumulation, accelerated differentiation, and augmented Srebp1 and lipogenic gene expression.
A: I1KD and control 3T3-L1 cells were differentiated at 5 mmol/L glucose concentration for 8 days when RNA was isolated and Srebp1c, Srebp1a,
Insig1, and Insig2 gene expression analyzed using quantitative RT-PCR (n = 6). I1KD vs controls: *P < 0.01, **P < 0.001. B: Western blot analysis
was performed in I1KD and control cells to assess mature SREBP1 levels. Mature SREBP1 was normalized to a-tubulin. The blot was quantified by
densitometry (n = 6). I1KD vs. controls: *P< 0.05. C: Photomicrographs of Oil-Red-O–stained I1KD and control 3T3-L1 cells, 8 days after induction
of differentiation at 5 mmol/L glucose. D: TG levels were measured 10 days after induction of differentiation at 5 mmol/L glucose of I1KD and
control cells (n = 3). I1KD vs. 5 mmol/L controls: **P< 0.001. E: Real time PCR analysis was performed on RNA, and gene expression levels of lipid-
related SREBP1 target genes were analyzed in cells differentiated in 5 mmol/L glucose (n = 6). I1KD vs. controls: *P < 0.05, **P < 0.01,***P <
0.001,****P < 0.0001. F: De novo FA synthesis radioactive assay was carried out in Insig1 KD and control cells at day 8 of differentiation after
overnight serum starvation and at the condition indicated (n = 8–9). I1KD vs. control: *P < 0.005. I1KD treated with C75 vs. control treated with
C75: &P < 0.001. Control vs. control treated with C75 and I1KD vs. I1KD treated with C75: #P < 0.01. Control vs control treated with insulin and
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subcutaneous depot mass (% of body weight) (Supple-
mentary Fig. 7D). Concerning the main metabolic param-
eter, such as food consumption (Supplementary Fig. 7E),
glucose tolerance (Supplementary Fig. 8A), insulin sensitiv-
ity (Supplementary Fig. 8B), respiratory exchange ratio
(Supplementary Fig. 8C), and energy expenditure (Supple-
mentary Fig. 8D), the mice in this model do not present any
difference with respect to their WT littermates. Concern-
ing blood biochemistry, the Insig1 KO mice show de-
creased TG compared with controls (Supplementary
Table 3). Moreover, Insig1 KO mice show an increased
number of smaller adipocytes in the gonadal WAT depot
(Supplementary Fig. 9).
We also performed transcriptional analysis of gonadal
WAT from the Insig1 KO model that revealed increased
Srebp1c and a trend for increased Srebp2 mRNA levels
(Fig. 5B). Protein analysis confirmed that the SREBP1
mature protein form was also increased (Fig. 5C). As seen
in I1KD 3T3-L1 adipocytes, no compensatory alteration in
Insig2 was observed, and in the context of preserved in-
sulin sensitivity, expression levels of Fas, Acc1, and Scd1
were increased in parallel with Srebp1c (Fig. 5D).
In vitro differentiation of primary cultures of Insig1 KO
WAT preadipocytes showed increased lipid accumulation
(Fig. 5E) and augmented expression of lipid accumulation
markers (e.g., adipose differentiation-related protein [Adrp]
and Perilipin) at day 4 of differentiation (Fig. 5F) compared
with WT counterparts. As shown for gonadal WAT gene
profiling performed on Insig1 KO, WAT primary culture
confirmed an increase in the expression of SREBP1 target
genes, including Scd1, Fas, and Acc1 (Fig. 5F).
Increased SCD1 activity in the WAT of Insig1 KO
mice associated with increased Scd1 expression.
Next, we assessed whether the depletion in Insig1 ex-
pression and associated upregulation of Scd1 affected the
FA composition of WAT in vivo. FA profiling of TGs
revealed a significant increase in the levels of oleate and
palmitoleate as well as an increase in the SCD1 ratio of the
essential free FAs of the Insig1 KO mouse compared with
WT mice (Table 1). Of note, we did not observe changes in
products of SCD1 or a change in the SCD1 ratio of the PLs
of the Insig1 WAT, consistent with defense of the PL
compartment. These analyses also identified an increased
amount of nonessential FAs in the TGs, consistent with
higher rates of de novo FA synthesis in this model. A
similar phenotype of preserved PL-to-SCD1 ratio with an
elevated TG-to-SCD1 ratio was also observed in the WAT
of ob/ob mice via two independent analyses (Supplemen-
tary Fig. 10A–D). Similarly, we checked if the observed
change in the Insig1/SREBP1 set point in WAT of MO
patients versus lean controls was associated with mainte-
nance of the pool of unsaturated FAs. Lipid composition of
SC WAT from lean (BMI 23.2 6 1.2 kg/m2) and MO (BMI
54.0 6 4.9 kg/m2, HOMA 4.0 6 1.4) (Supplementary Table
1, cohort 5) revealed that the absolute amount of un-
saturated FAs was conserved between the two groups.
Moreover, we observed significant reduction of specific
saturated FAs (20:0, 22:0) in WAT of MO versus lean control
subjects (Supplementary Table 2). This result agrees with
our recent analysis of WAT of weight-discordant mono-
zygotic cotwins, showing that obese twins have a re-
duction in specific saturated FAs (e.g., 12:0, 18:0, and
20:0) and increased proportion of specific unsaturated
FAs such as palmitoleic (16:1n-7) and arachidonic acid
(20:4n-6) (2).
DISCUSSION
Here, we present strong supporting evidence for an
adaptive mechanism designed to maintain cellular FA
unsaturation when WAT is under adverse metabolic con-
ditions imposed by obesity and IR. This adaptive response
involves facilitated lipid biosynthesis mediated by down-
regulation of Insig1 and optimized activation of SREBP1
and SCD1. This change in the set point of the Insig1/
SREBP1 regulatory feedback loop helps to maintain lipid
desaturation of adipocytes in a situation of metabolic
stress.
Using genetically modified in vitro and in vivo models,
we have shown that downregulation of Insig1 per se
facilitates TG accumulation in parallel with favored bio-
synthesis of unsaturated lipids through preferential in-
duction of SCD1. We observed this downregulation of
Insig1 in WAT of dietary and genetic mouse models of
obesity-induced IR, in obese and MO IR humans, and in
cellular models of IR.
Our data indicate that it is the IR associated with obe-
sity, more than the amount of fat stored, that is the main
factor responsible for the decreased Srebp1c WAT mRNA
expression observed in MO individuals. Insig1 mRNA ex-
pression is decreased in the SC depot of MO individuals
compared with obese patients and is further reduced in the
presence of IR. On the basis of the role of Insig1 control-
ling SREBP1 activation, the decrease in Insig1 is expected
to help to maintain the levels of the active form of SREBP1.
From the clinical perspective, this change in set point may
be important to reconcile the perceived paradox between
the excessive amounts of lipids that MO individuals are able
to store in their WAT despite their IR and decreased mRNA
expression of fundamental prolipogenic genes such as
Srebp1 (39–41).
We found that reducing Insig1 mRNA to a similar de-
gree observed in MO human WAT accelerates adipocyte
differentiation and enhances lipogenesis, and conse-
quently, lipid accumulation. Notably, the effect of Insig1
KD enhancing lipid accumulation in 3T3-L1 adipocytes
could be reproduced in conditions that mimicked both
physiological and pathophysiological glucose levels. In our
opinion, these data indicate that the regulation of Insig1 in
WAT may be more important under conditions of IR and
metabolic stress than for the adipose tissue expansion
observed in anabolic states.
Maintenance of SREBP1 mature protein levels in morbid
obesity or under IR conditions is not associated with
conserved global expression or restoration of all known
SREBP1 target genes. Indeed, genes involved in the early
stages of de novo lipogenesis from glucose, such as Acc1
and Fas, were downregulated in WAT of MO IR patients, in
our DIO and ob/ob IR mouse models, and in our IR in vitro
model, despite maintained levels of mature SREBP1. This
suggests that other transcription factors regulated by glu-
cose, such as ChREBP, may be required for their full
expression. Moreover, it has been shown that in livers of
HFD-fed C57BL6 mice, there is upregulation of SREBP1
I1KD vs. I1KD treated with insulin: ^P < 0.005. Control treated with insulin vs. I1KD treated with insulin: $P < 0.005. G: Lipidomic analysis and
subsequent evaluation of SCD1 activity were performed in I1KD and control cells. Cells were harvested at day 8 of differentiation and processed as
described in RESEARCH DESIGN AND METHODS (n = 12). I1KD vs. controls: *P < 0.05, **P < 0.01. Data are presented as mean 6 SEM.
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and preferentially SCD1 as its target gene compared with
unaltered FAS expression (42). Conversely, pathways
involved in modification of the FA chain or FA storage,
such as Scd1, Ccta, Gpat1, and Dgat1, were maintained to
a greater extent in obese subjects, being closer to those
observed in lean individuals.
One of the most revealing findings, both in vivo and in
vitro, is the identification of SCD1 as a preferentially
FIG. 5. Insig1 depletion in vivo and in vitro shows increased fat accumulation, SREBP1 levels, and SREBP1 target gene expression. A: Percentage
of fat mass with respect to body weight was established for Insig1 KO males (n = 6) vs. WT littermates (n = 8). B and D: Real-time PCR analysis was
performed on gonadal WAT from 11-week-old male Insig1 KO (n = 5) and WT littermates (n = 4). C: Mature SREBP1 levels in gonadal WAT of
Insig1 KO (n = 5) and WT littermates (n = 4). E: Oil-Red-O staining of WT and Insig1 KO primary adipocytes at day 4 and 8 of differentiation. Cells
were induced to differentiate with a standard MDI induction cocktail using Dulbecco’s modified Eagle’s medium with 25 mmol/L glucose. F: Gene
expression analysis of Insig1 KO and WT WAT primary culture after 4 days of differentiation (n = 3–4). Insig1 KO vs. WT: *P < 0.05, **P < 0.01,
***P < 0.0001. Data are presented as mean 6 SEM.
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regulated target for Insig1/SREBP1. From an adaptive
perspective, maintenance of a proper degree of unsatura-
tion could be the main homeostatic function of this regu-
latory loop. This view is supported by the fact that in our in
vitro studies, inactivation of Insig1 under both physio-
logical and high glucose conditions preferentially induced
Scd1 gene expression and consequently an increase in
SCD1-dependent lipid unsaturation indexes such as
C18:1n9/18:0, C16:1n7/16:0 (43,44), and C14:1n5/14:0 (45).
To consolidate the concept that downregulation of
Insig1 promotes a prolipogenic effect in WAT, we gener-
ated an Insig1 KO mouse. This murine model allowed us
to study the effect of Insig1 depletion without the con-
founding effects of obesity and/or IR. Mice lacking intact
Insig1 are characterized by an increased percentage of fat
mass with respect to WT littermates. Also primary cultures
of Insig1 KO preadipocytes showed increased and accel-
erated lipid accumulation after induction of differentiation,
as previously observed in the Insig1 KD 3T3-L1. These
previous results led us to hypothesize that the adaptive
changes in Insig1/SREBP1 set point will maintain the pool
of unsaturated FAs in WAT. Lipid composition analysis
performed on WAT of MO versus lean control subjects
supports this concept, because the absolute amount of
unsaturated FA was maintained at similar levels in both
groups. Most interestingly, profiling of specific lipid spe-
cies in WAT of our models of genetic-induced obesity and
IR, as well as our Insig1 KO mouse, indicated that the level
of unsaturation and SCD1 activity is specifically main-
tained in the membrane PL fraction.
This result strengthens our previous observation that in
weight-discordant monozygotic twin pairs (2), the obese
cotwins displayed reduced specific saturated FA and aug-
mented proportions of specific unsaturated Fas, such as
palmitoleate, in membrane PL, alongside increases in indexes
reflecting augmented activity of desaturation enzymes.
In summary, our results indicate the existence of an
adaptive response in human WAT involving changes in the
set point of the Insig1/SREBP1/SCD1 axis in order to op-
timize lipogenic gene expression programs that ensure
availability of structural and biologically essential unsat-
urated lipids under disadvantageous metabolic conditions
such as obesity or IR. Thus, defects in insulin-regulated
lipid metabolism associated with IR may at least be par-
tially ameliorated by a reduction of Insig1 and optimized
maturation of the active form of SREBP1 as a consequence
of a resetting of the Insig1/SREBP1 negative regulatory
feedback loop (Supplementary Fig. 12).
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